文献速递肝病消化道肿瘤与早癌

抗病毒治疗病毒学应答对慢性乙型肝炎病毒感染合并失代偿期肝硬化患者短期和长期结局的影响

Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-05-09

该研究基于韩国失代偿期肝硬化队列中295例失代偿后立即接受恩替卡韦(n=179)或拉米夫定(n=116)治疗的患者,分析维持病毒学应答(MVR)与短期(6个月)和长期(6-120个月)无肝移植生存的关系。中位生存时间7.7年,5年无肝移植生存率60.1%、10年45.7%;MVR与长期无肝移植生存最强相关,基线MELD评分>20和多种并发症与短期死亡相关;MVR患者肝功随时间显著改善,但肝癌风险或肝癌相关死亡风险降低不显著。

要点

  • MVR是长期无肝移植生存最强相关因素,获益可维持长达10年。
  • 基线MELD评分>20和多种并发症与短期死亡相关。
  • MVR患者肝功随时间显著改善,但肝癌风险或肝癌相关死亡风险降低不显著。

核心结论

  • 在韩国HBV相关失代偿期肝硬化患者10年观察研究中,基线MELD评分和恩替卡韦或拉米夫定的MVR与短期和长期无肝移植生存相关。
  • MVR的获益在失代偿后仍可维持长达10年,但患者仍有肝癌风险。

研究设计与样本

  • 采用韩国肝硬化流行病学与自然史研究数据进行的10年观察分析。
  • 全队列为2005年起失代偿发生时入组的1595例患者,本分析纳入失代偿后立即开始治疗的患者295例。
  • 治疗药物为恩替卡韦(n=179)或拉米夫定(n=116)。
  • 收集实验室检查结果、肝癌发生数据以及Child-Turcotte-Pugh评分和终末期肝病模型(MELD)评分。
  • 平均随访时间为62.3±36.5个月,主要终点为无肝移植生存时间。

主要发现

  • 中位生存时间为7.7年;60.1%的患者生存5年,45.7%的患者无肝移植生存10年。
  • 116例患者(39.3%)观察到MVR,这些患者的无肝移植生存时间显著长于无MVR患者。
  • 生存时间与肝癌发生相关;无肝癌患者若在开始抗病毒治疗后存活第一个6个月则生存极好,而肝癌患者的生存率随时间持续下降。
  • 基线MELD评分高于20和多种并发症与短期死亡相关。
  • 接受恩替卡韦的患者10年生存比例显著高于接受拉米夫定的患者,但在MVR患者中未观察到差异。

关键数值与推荐

  • MVR定义为治疗期间持续检测不到HBV DNA。
  • 短期生存指6个月,长期生存指6-120个月。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • MVR患者肝功随时间显著改善,但肝癌风险或肝癌相关死亡风险的降低不显著。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Little is known about the effects of antiviral therapy on short- and long-term survival of patients with hepatitis B virus (HBV)-related decompensated cirrhosis. We aimed to determine whether a maintained virologic response (MVR, defined as persistent undetectable HBV DNA during therapy) associates with short-term (6 mo) and long-term (6-120 mo) survival of patients with decompensated cirrhosis. METHODS: We performed a 10-year observation analysis using data from the Epidemiology and Natural History of Liver Cirrhosis study of patients with decompensated liver cirrhosis in Korea. Of the entire cohort (1595 patients enrolled at onset of decompensation since 2005), our analysis comprised 295 patients who immediately began treatment with entecavir (n = 179) or lamivudine (n = 116) after decompensation. We collected laboratory test results, data on hepatocellular carcinoma (HCC) development, and Child-Turcotte-Pugh and model for end-stage liver disease (MELD) scores. The mean follow-up time was 62.3 ± 36.5 months. The primary end point was time of liver transplant-free survival. RESULTS: The median survival time was 7.7 years; 60.1% of patients survived for 5 years and 45.7% survived for 10 years without liver transplantation. An MVR was observed in 116 patients (39.3%); these patients had significantly longer times of transplant-free survival than patients without MVR. Survival times associated with the occurrence of HCC; survival of patients without HCC was excellent if they survived the first 6 months after initiation of antiviral therapy, whereas the survival rates of patients with HCC decreased persistently over time. A baseline MELD score above 20 and multiple complications were associated with short-term mortality. MVR was the factor most strongly associated with long-term transplant-free survival. Significantly higher proportions of patients who received entecavir survived 10 years compared with patients who received lamivudine, but no difference was observed among patients with MVRs. Patients with MVRs had significant improvement in hepatic function over time, but nonsignificant reductions in risk of HCC or HCC-related mortality. CONCLUSIONS: In a 10-year observation study of patients in Korea with HBV-related decompensated cirrhosis, we found baseline MELD score and MVR to entecavir or lamivudine to associate with short- and long-term transplant-free survival. The benefits of an MVR are maintained for up to 10 years even after decompensation, but patients are still at risk for HCC.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Jang JW, Choi JY, Kim YS, et al. Effects of Virologic Response to Treatment on Short- and Long-term Outcomes of Patients With Chronic Hepatitis B Virus Infection and Decompensated Cirrhosis. Clin Gastroenterol Hepatol. 2018. PMID: 29753085. doi:10.1016/j.cgh.2018.04.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。